clinical trial · NCT06698965
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Shanghai Chest Hospital·phase2·recruiting·n = 52
Lung Cancer, Small CellChemotherapy （Etoposide and Carboplatin）Immunotherapy （Envafolimab）Trilaciclib
brief summary
This prospective, randomized, controlled phase II study aims to evaluate the efficacy of combination therapy with Envafolimab and chemotherapy in first-line extensive stage SCLC, as well as the impact of Trilaciclib on the incidence of myelosuppression and anti-tumor effects in patients.
started
Oct 13, 2024
primary completion
Oct 31, 2029
completion
Oct 31, 2029
last updated
Nov 21, 2024
official title
A Randomized, Controlled Phase II Clinical Study on the Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol